CYTOTIL Trademark

Trademark Overview

On Wednesday, May 10, 2023, a trademark application was filed for CYTOTIL with the United States Patent and Trademark Office. The USPTO has given the CYTOTIL trademark a serial number of 97928862. The federal status of this trademark filing is PUBLICATION/ISSUE REVIEW COMPLETE as of Monday, October 27, 2025. This trademark is owned by Obsidian Therapeutics, Inc.. The CYTOTIL trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

medical and scientific research and development services in the fields of cell therapy, gene therapy, oncology, and immunotherapy
cytotil

General Information

Serial Number97928862
Word MarkCYTOTIL
Filing DateWednesday, May 10, 2023
Status681 - PUBLICATION/ISSUE REVIEW COMPLETE
Status DateMonday, October 27, 2025
Registration Number0000000
Registration DateTuesday, November 18, 2025
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements

Goods and Servicesmedical and scientific research and development services in the fields of cell therapy, gene therapy, oncology, and immunotherapy

Classification Information

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateThursday, June 8, 2023
Primary Code042
First Use Anywhere DateMonday, September 30, 2019
First Use In Commerce DateMonday, September 30, 2019

Trademark Owner History

Party NameObsidian Therapeutics, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressCambridge, MA 02138

Trademark Events

Event DateEvent Description
Saturday, May 13, 2023NEW APPLICATION ENTERED
Thursday, June 8, 2023NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, September 14, 2023ASSIGNED TO EXAMINER
Monday, September 18, 2023NON-FINAL ACTION WRITTEN
Monday, September 18, 2023NON-FINAL ACTION E-MAILED
Monday, September 18, 2023NOTIFICATION OF NON-FINAL ACTION E-MAILED
Thursday, December 14, 2023APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Thursday, December 14, 2023APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Monday, March 18, 2024TEAS RESPONSE TO OFFICE ACTION RECEIVED
Monday, March 18, 2024CORRESPONDENCE RECEIVED IN LAW OFFICE
Monday, March 18, 2024TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, April 17, 2024FINAL REFUSAL WRITTEN
Wednesday, April 17, 2024FINAL REFUSAL E-MAILED
Wednesday, April 17, 2024NOTIFICATION OF FINAL REFUSAL EMAILED
Thursday, May 23, 2024APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Thursday, May 23, 2024APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Thursday, October 17, 2024TEAS REQUEST FOR RECONSIDERATION RECEIVED
Thursday, October 17, 2024TEAS AMENDMENT OF USE RECEIVED
Thursday, October 17, 2024USE AMENDMENT FILED
Thursday, October 17, 2024AMENDMENT TO USE PROCESSING COMPLETE
Thursday, November 21, 2024USE AMENDMENT ACCEPTED
Thursday, November 21, 2024NON-FINAL ACTION WRITTEN
Thursday, November 21, 2024NON-FINAL ACTION E-MAILED
Thursday, November 21, 2024NOTIFICATION OF NON-FINAL ACTION E-MAILED
Wednesday, February 19, 2025APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Wednesday, February 19, 2025APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Wednesday, May 21, 2025TEAS RESPONSE TO OFFICE ACTION RECEIVED
Wednesday, May 21, 2025CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, May 21, 2025TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, July 9, 2025SUBSEQUENT FINAL REFUSAL WRITTEN
Wednesday, July 9, 2025SUBSEQUENT FINAL EMAILED
Wednesday, July 9, 2025NOTIFICATION OF SUBSEQUENT FINAL EMAILED
Friday, September 26, 2025EXAMINERS AMENDMENT -WRITTEN
Friday, September 26, 2025EXAMINERS AMENDMENT E-MAILED
Friday, September 26, 2025NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Friday, September 26, 2025EXAMINER'S AMENDMENT ENTERED
Thursday, October 16, 2025APPROVED FOR REGISTRATION SUPPLEMENTAL REGISTER

Related Keywords

cytotil therapy gene oncology immunotherapy cell fields scientific research development services